B型肝炎ウイルス(HBV)治療薬の世界市場予測・分析(~2024)...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Overview 25
3.2 Etiology and Pathophysiology 26
3.2.1 Etiology 26
3.2.2 Pathophysiology 33
3.3 Symptoms 35
3.4 Prognosis 36
3.4.1 Phases of Chronic HBV Infection 37
3.4.2 Complications of Chronic Hepatitis B 41
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.3 Global Trends 47
4.4 Forecast Methodology 49
4.4.1 Sources Used 50
4.4.2 Sources Not Used 58
4.4.3 Forecast Assumptions and Methods 59
4.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 65
4.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 65
4.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 67
4.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 70
4.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 72
4.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 74
4.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 75
4.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 76
4.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 77
4.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 79
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 80
4.6.3 Strengths of the Analysis 81
5 Disease Management 82
5.1 Diagnosis and Treatment Overview 82
5.1.1 Diagnosis 82
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 83
5.1.3 Clinical Practice 85
5.2 US 90
5.2.1 Screening and Diagnosis 91
5.2.2 Clinical Practice 92
5.3 5EU 95
5.3.1 Screening and Diagnosis 96
5.3.2 Clinical Practice 97
5.4 Japan 101
5.4.1 Screening and Diagnosis 101
5.4.2 Clinical Practice 103
5.5 China 106
5.5.1 Screening and Diagnosis 107
5.5.2 Clinical Practice 109
6 Competitive Assessment 113
6.1 Overview 113
6.2 Product Profiles – Major Brands 117
6.2.1 Baraclude (entecavir) 117
6.2.2 Viread (tenofovir disoproxil fumarate) 122
6.2.3 Pegasys (peginterferon alfa-2a) 130
6.2.4 Hepsera (adefovir dipivoxil) 137
6.2.5 Tyzeka (telbivudine) 141
6.3 Other Therapeutics 147
6.3.1 Conventional and Pegylated Interferon alfa 147
6.3.2 Nucleos(t)ide Analogs 148
7 Unmet Needs and Opportunities 150
7.1 Overview 150
7.2 Improvements in Long-Term Clinical Outcomes 153
7.2.1 Unmet Need 153
7.2.2 Gap Analysis 156
7.2.3 Opportunity 160
7.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates 163
7.3.1 Unmet Need 163
7.3.2 Gap Analysis 167
7.3.3 Opportunity 167
7.4 Increased Access to Treatment 168
7.4.1 Unmet Need 168
7.4.2 Gap Analysis 171
7.4.3 Opportunity 172
7.5 Drugs That Effectively Target and Suppress HBV cccDNA 173
7.5.1 Unmet Need 173
7.5.2 Gap Analysis 173
7.5.3 Opportunity 174
7.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients 175
7.6.1 Unmet Need 175
7.6.2 Gap Analysis 176
7.6.3 Opportunity 177
7.7 Overcome Unique Barriers Posed by China’s Healthcare System 178
7.7.1 Unmet Need 178
7.7.2 Gap Analysis 179
7.7.3 Opportunity 179
8 Pipeline Assessment 181
8.1 Overview 181
8.2 Clinical Trial Mapping 182
8.2.1 Clinical Trials by Phase and Status, Therapy Class, and Location 182
8.3 Promising Drugs in Clinical Development 184
8.3.1 Tenofovir Alafenamide Fumarate 187
8.3.2 ARC-520 194
8.3.3 GS-9620 201
8.3.4 GS-4774 206
8.4 Other Drugs in Development 212
8.4.1 ABX-203 213
8.4.2 REP 2139-Ca 214
8.4.3 Besifovir 215
8.4.4 Hepabulin 215
8.4.5 Myrcludex-B 215
8.4.6 Agents in Early Stages of Development 216
9 Current and Future Players 219
9.1 Overview 219
9.2 Trends in Corporate Strategy 222
9.3 Company Profiles 225
9.3.1 Gilead 225
9.3.2 Bristol-Myers Squibb 227
9.3.3 Roche 229
9.3.4 Merck 230
9.3.5 GSK 233
9.3.6 Novartis 234
9.3.7 Arrowhead Research 235
9.3.8 GlobeImmune 236
10 Market Outlook 237
10.1 Global Markets 237
10.1.1 Forecast 237
10.1.2 Drivers and Barriers – Global Issues 243
10.2 US 245
10.2.1 Forecast 245
10.2.2 Key Events 249
10.2.3 Drivers and Barriers 250
10.3 5EU 252
10.3.1 Forecast 252
10.3.2 Key Events 256
10.3.3 Drivers and Barriers 257
10.4 Japan 260
10.4.1 Forecast 260
10.4.2 Key Events 264
10.4.3 Drivers and Barriers 265
10.5 China 266
10.5.1 Forecast 266
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 271
11 Appendix 274
11.1 Bibliography 274
11.2 Abbreviations 296
11.3 Methodology 302
11.4 Forecasting Methodology 302
11.4.1 Total Prevalent Cases of Chronic Hepatitis B 302
11.4.2 Diagnosed Chronic Hepatitis B Patients 303
11.4.3 Percent Drug-Treated Chronic Hepatitis B Patients 303
11.4.4 Drugs Included in Each Therapeutic Class 304
11.4.5 Launch and Patent Expiry Dates 304
11.4.6 General Pricing Assumptions 305
11.4.7 Individual Drug Assumptions 307
11.4.8 Generic Erosion 314
11.4.9 Pricing of Pipeline Agents 315
11.5 Primary Research – KOLs Interviewed for this Report 316
11.6 Primary Research – Prescriber Survey 319
11.7 About the Authors 320
11.7.1 Analyst 320
11.7.2 Therapy Area Director 320
11.7.3 Epidemiologists 321
11.7.4 Global Director of Therapy Analysis and Epidemiology 321
11.7.5 Global Head of Healthcare 321
11.8 About GlobalData 322
11.9 Disclaimer 322


【レポート販売概要】

■ タイトル:B型肝炎ウイルス(HBV)治療薬の世界市場予測・分析(~2024)
■ 英文:PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
■ 発行日:2016年1月1日
■ 調査会社:GlobalData
■ 商品コード:GDHC117PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。